Nasacort, Flonase Competition Heats Up As Sanofi Appeals NAD Review
This article was originally published in The Tan Sheet
Executive Summary
Chattem appeals a National Advertising Division decision from a review of advertising comparing its Nasacort nasal allergy spray to GSK’s Flonase. The Sanofi business maintains NAD relied on a “cookbook” approach to determine whether claims for the product are substantiated.